<DOC>
	<DOCNO>NCT01258712</DOCNO>
	<brief_summary>This Phase III study evaluate efficacy safety Tocilizumab patient Rheumatoid Arthritis .</brief_summary>
	<brief_title>Study Tocilizumab Combination With Methotrexate Treatment Moderate Severe Rheumatoid Arthritis Patients</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Patients diagnose history moderateto severe rheumatoid arthritis 6 month accord American College Rheumatology ( ACR ) 1987 revise criterion classification RA . Patients fail achieve clinical response treatment least 2 DMARDs ( disease modify antirheumatic drug ) ( include MTX ) least 12 week within 12 month prior screen , MTX must stable dose 1020 mg/wk least 12 week prior screen . All DMARDs give standard therapeutic dose . Patients satisfy swollen joint count ( SJC ) ≥ 6 ( 66 joint count ) tender joint count ( TJC ) ≥ 8 ( 68 joint count ) screen baseline . Creactive protein ( CRP ) level ≥ 1 mg/dl erythrocyte sedimentation rate ( ESR ) ≥ 28 mm/hour screen baseline . Patients receive major surgery include joint surgery 8 week prior screen schedule operate within 6 month enrolment . Patients rheumatoid autoimmune disease RA , include limited SLE ( system lupus erythematosus ) , significant systemic involvement secondary RA . Patients belong Class IV ACR classification criterion functional status RA . ( ACR Amended Criteria Classification Functional Capacity Rheumatoid Arthritis ; Class IV : Largely wholly incapacitated patient bedridden confine wheel chair , permit little selfcare ) . Patients history hypersensitivity human , humanize murine monoclonal antibody patient contraindication . Patients currently history recurrence bacterial , viral , fungal , mycobacterial infection infectious disease ; tuberculosis ( TB ) , atypical mycobacterial disease , clinically significant granulomatous disease chest radiograph , hepatitis B , hepatitis C , herpes zoster etc . However , patient hand &amp; foot fungal infection participate .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>